At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 28 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at real-world experience of using nemolizumab (Nemluvio®) to treat moderate-to-severe atopic dermatitis (a type of eczema) in people aged 12 and over. It is run by Galderma R&D.
Who can take part
- People aged 12 or over with moderate-to-severe atopic dermatitis
- Starting treatment with nemolizumab (Nemluvio®), as decided by their doctor and in line with the medicine's label
- The person, or their legal representative, has signed the informed consent form
Who may not be able to
- People who cannot take nemolizumab (Nemluvio®) according to the medicine's label
- People who took an experimental (investigational) drug within 3 months before the start of the study
- People who have taken nemolizumab before
- People who cannot understand the consent form or complete the study questionnaires due to mental, physical, or language difficulties
What taking part involves
- • Taking nemolizumab (Nemluvio®) as prescribed by your doctor, in line with the medicine's label
- • Completing study questionnaires
Time commitment: Not stated — ask the trial team about how many visits there are, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 12 Years and over
- Who
- All
- Number of participants
- 1,000
- Started
- 2025-07-14
- Last checked
- 2025-11
Plain English Summary
What is this study?
- • Testing a new treatment for atopic dermatitis
- • Clinical study - 1,000 participants
- • The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6
Who can take part?
- • Ages 12 Years and over
- • Diagnosed with atopic dermatitis
Where?
- • London - Galderma Investigational Site 5408
- • Southampton - Galderma Investigational Site 6401
- • Watford - Galderma Investigational Site 6399
- • Kings Lynn - Galderma Investigational Site 6400
- • +20 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
More detail
This prospective, multicenter, non-interventional study (NIS) seeks to evaluate treatment with nemolizumab of moderate-to-severe AD in adolescents and adults over an approximately 12-month period using physician assessments in routine clinical practice and PRO measures. Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. The visit structure is not defined by the study protocol but is determined by routine medical practice. The visit schedule is intended to facilitate a systematic data assessment according to clinical routine. A sub-study will be completed in Germany and the UK at selected sites in which participants will complete the Peak Pruritus (PP) Numerical Rating Scale (NRS), Average Pruritus (AP) NRS, Sleep Disturbance (SD) NRS, and Pain NRS on a daily basis from Day -1 to Day 14. Data collection will occur remotely, and no clinic visits will be required.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 12 Years and over
- Who can join: All genders
What the study is looking for
- ✓Participants who, according to the treating physician's decision and in line with the local package label, start...
- ✓Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
- ✓Participants who signed the written agreement to take part form (ICF) or had it signed by their legal representative.
Who cannot take part
- ✗Have safety concern(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
- ✗Participants who received treatment with a drug under clinical development/investigation within 3 months prior to...
- ✗Participants who received nemolizumab previously.
- ✗Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to...
See the full criteria
Where Is This Study? (24 UK sites)
Galderma Investigational Site 5408
London NW3 2QG, United Kingdom
Galderma Investigational Site 6401
Southampton SO16 6YD, United Kingdom
Galderma Investigational Site 6399
Watford WD18 0HB, United Kingdom
Galderma Investigational Site 6400
Kings Lynn PE30 4ET, United Kingdom
Galderma Investigational Site 5131
Harrogate HG2 7SX, United Kingdom
Galderma Investigational Site 6389
Sheffield S10 2TH, United Kingdom
Galderma Investigational Site 6395
London SE5 9RS, United Kingdom
Galderma Investigational Site 6392
Birmingham B15 2GW, United Kingdom
Galderma Investigational Site 6404
Leeds LS9 7TF, United Kingdom
Galderma Investigational Site 6397
York YO31 8HE, United Kingdom
Galderma Investigational Site 6375
Bridgend CF31 1RQ, United Kingdom
Galderma Investigational Site 6388
Epsom KT18 7EG, United Kingdom
Galderma Investigational Site 6394
Harrow HA3 7LT, United Kingdom
Galderma Investigational Site 6393
Kingston upon Thames KT2 7QB, United Kingdom
Galderma Investigational Site 6666
Kirkcaldy KY2 5AH, United Kingdom
Galderma Investigational Site 6415
Liverpool L14 5AB, United Kingdom
Galderma Investigational Site 5210
London E11 1NR, United Kingdom
Galderma Investigational Site 6368
London SE1 9RT, United Kingdom
Galderma Investigational Site 6396
Manchester M23 2SY, United Kingdom
Galderma Investigational Site 6402
Metropolitan Borough of Wirral CH49 5PE, United Kingdom
Galderma Investigational Site 5431
Redhill RH1 5RH, United Kingdom
Galderma Investigational Site 6403
Sandbach CW11, United Kingdom
Galderma Investigational Site 5989
Swansea SA2 8QA, United Kingdom
Galderma Investigational Site 5944
Wolverhampton WV10 0QP, United Kingdom
How to Get in Touch
Galderma Research and Development
Sponsor contactCONTACT